StreetAlpha.app
Home › Stocks › XERS

Xeris Biopharma Holdings, Inc. (XERS)

Healthcare
$16.80
▲ +0.60%
LAST CLOSE · NOV 17

Xeris is a biopharmaceutical company in Chicago that sells medicines for rare endocrine and neurological diseases. It last closed at $16.80 on Nov 17, up 0.60% on the day. The average 12-month price target from 5 analysts is $17.00 (+1.2% from the last close), with a high of $21.00 and a low of $12.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $746K, the largest $746K.

AI Auto Pilots
Is XERS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$368.3M
+38.4% vs a year ago
Net income
−$6.5M
−1.8% margin
EPS (diluted)
−$0.03
Operating margin
12.7%
$46.8M operating income
Valuation
Market cap
$3.1B
182.7M shares
P/E
–
No P/E while losing money
Price to sales
8.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$131.1M
At Sep 30
Debt
$189.7M
At Sep 30
Shareholder equity
$48.8M
Shares outstanding
182.7M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $49.6M$49.6MFY2021FY2022: $110.2M$110.2MFY2022FY2023: $163.9M$163.9MFY2023FY2024: $203.1M$203.1MFY2024FY2025: $291.8M$291.8MFY2025

From XERS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
4 Buy1 Hold0 Sell
Each firm's latest rating on XERS in the past 90 days
Average 12-month target
$17.00
▲ 1.2% upside

Based on 5 analysts who set a price target on XERS in the past 90 days. The average target is $17.00, with a high of $21.00 and a low of $12.00, compared with the last close of $16.80.

Low $12.00Avg $17.00High $21.00
Blue marker: last close $16.80
Highest target$21.00
Average target$17.00
Lowest target$12.00
Latest rating changes
BarclaysTarget raised
Nov 11Buy$14 → $18
OppenheimerReiterated
Nov 6Buy$21
Piper SandlerReiterated
Nov 6Hold$12
HC Wainwright & Co.Maintained
Nov 6Buy$18
BarclaysTarget raised
Oct 6Buy$12 → $14
DateFirmActionRatingPrice target
Nov 11BarclaysTarget raisedBuy$14 → $18
Nov 6OppenheimerReiteratedBuy$21
Nov 6Piper SandlerReiteratedHold$12
Nov 6HC Wainwright & Co.MaintainedBuy$18
Oct 6BarclaysTarget raisedBuy$12 → $14
Loading…

Technical Analysis

XERS · as of the Nov 17 close · updated after every close
Uptrend, overbought

The stock is 23% above its 20 day and 36% above its 50 day average. It is 53% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 86), overbought. The nearest support is the Pivot at $16.71, and the nearest resistance the 52 week high at $16.98.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 4.3%/day
Key levels
$17.03Pivot R1+1.4%
$16.9852 week high+1.1%
$16.80Last close
$16.71Pivot−0.5%
$16.48Pivot S1−1.9%
$12.9420 day average−23.0%
$10.7350 day average−36.1%
$10.10Swing low (Nov 2)−39.9%
$9.57100 day average−43.0%
$7.92200 day average−52.9%
$5.2552 week low−68.8%
Indicators
RSI (14)85.79Overbought above 70Overbought
MACD1.85Above its signal lineBullish
Stochastic96.7Near the top of its rangeOverbought
ADX (14)50.5Strong uptrend
Williams %R-2.7Oversold below −80, overbought above −20Overbought
CCI (20)97.9Oversold below −100, overbought above 100Neutral
Rate of change+62.3%Change over 10 sessionsBullish
ATR (14)$0.72Typical daily range, 4.3% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for XERS

What happened before

See how XERS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow XERS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How XERS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in XERS in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$746K
Largest print
$746K
Loading…

XERS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲136 buying vs 98 selling
  • ▲Held by funds +2.8 pts
  • ▲Funds holding +9
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding250241+3.7%
In funds' top 10330.0%
Held by funds62.0%59.3%+2.8 pts
New / increased33 / 10334 / 106−2.9%
Reduced / sold out74 / 2465 / 30+3.2%
Put/call ratio0.000.81−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XERS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XERS is in one of them and how their past XERS trades turned out.

XERS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XERS in an article yet. Here's the latest on the wider market.

About Xeris Biopharma Holdings

Xeris is a biopharmaceutical company based in Chicago, Illinois, that develops and sells medicines for chronic endocrine and neurological diseases in the United States. Its marketed products include Recorlev for Cushing's syndrome, Gvoke, a glucagon treatment for severe low blood sugar, and Keveyis for primary periodic paralysis. Its customers include patients and the clinicians who treat them, and it is developing a weekly injectable form of levothyroxine for hypothyroidism.

Headquarters
Chicago, IL